Lineage Cell Therapeutics, Inc.
Price Action
Technical Summary
WEAKENINGLineage Cell Therapeutics, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 20), showing significant lag compared to the market leaders. Earnings contraction of 7% provides fundamental context to the price action. Investors should exercise caution due to high volatility (63% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.24 | +8.74% | ABOVE |
| 50 SMA | $1.35 | +0.20% | ABOVE |
| 100 SMA | $1.51 | -10.45% | BELOW |
| 150 SMA | $1.57 | -13.81% | BELOW |
| 200 SMA | $1.60 | -15.47% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LCTX in an uptrend right now?
LCTX has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is LCTX overbought or oversold?
LCTX's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is LCTX outperforming the market?
LCTX has a Relative Strength (RS) Rating of 20 out of 99. LCTX is currently lagging the broader market.
Where is LCTX in its 52-week range?
LCTX is trading at $1.35, which is 65% of its 52-week high ($2.09) and 40% above its 52-week low ($0.85).
How volatile is LCTX?
LCTX has a Beta of 1.57 and 52-week volatility of 63%. It's more volatile than the S&P 500 - expect bigger swings.